NovaQuest Private Equity Acquires Majority Interest in Clinical Ink

May 15, 2018
By Applied Clinical Trials Editors

Clinical Ink, the pioneering provider of eSource and next-generation ePRO/eCOA solutions for clinical development, announced that the private equity team at NovaQuest has acquired a majority of the outstanding shares of the company from existing investors and provided a substantial infusion of additional growth capital.

Read the full release here.

native1_300x100
lorem ipsum